Browse Articles

Discover research articles across all indexed journals

Association of PSMA PET results at biochemical recurrence (BCR) with metastasis free survival (MFS) by conventional imaging (CI) in patients with locally advanced or high-risk localized prostate cancer initially treated with radical prostatectomy (RP): A retrospective multicenter study.

Journal of Clinical Oncology Jesus Eduardo Juarez Casillas, Thomas A. Hope, Jeremie Calais et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.355

355 Background: Prostate-specific membrane antigen (PSMA) positron emission tomography-computed (PET-CT) is used to stage prostate cancer (PCa) at BCR. PSMA PET-CT imaging has shown high sensitivity in detecting disease at slight prostate specific antigen (PSA) rise compared to CI. There remains an evidence gap in understanding the implications on treatment decision and clinical outcomes of PSMA-PET CT results at BCR after RP. We investigated the association of PSMA PET results with outcomes specific to MFS by CI in patients with BCR of locally advanced or high risk localized (LAHR) PCa treated with RP. Methods: We retrospectively screened from two academic centers patients with LAHR PCa who developed BCR after receiving RP as definitive therapy and underwent PSMA PET-CT imaging. We collected baseline characteristics including age at diagnosis, BMI, race and ethnicity, T-staging, Gleason score, and PSA. Interval treatment changes after and up to 60-days post BCR were captured. Outcomes were evaluated from 60-days post BCR. We estimated MFS by CI. A Time-to-Event (TTE) analysis was conducted between PSMA PET+ and PSMA PET- patients to estimate the effect of PSMA PET results on MFS by CI. PSMA PET+ status is defined as having evidence of a distant lesion by PSMA PET. 1:1 Propensity Score Matching (PSM) was applied to adjust for confounders using a 0.2 caliper between both groups. Results: We retrospectively identified a total of 333 LAHR RP patients with receipt of PSMA PET at BCR between January 2016 - January 2024. The median age at diagnosis was 63, with majority of patients being white (74.4%), while 4.1% were Black or African American and 6.2% were Hispanic or Latino. Patients had a median PSA at BCR of 1.1 ng/mL and 77.3% had a Gleason Score of 8 or higher. After adjusting for PSA at BCR and interval treatment changes, 111 PSMA PET+ and 111 PSMA PET- patients were included in the analysis. The overall median follow-up time was 47.3 (IQR: 21.2, 72.8) months. MFS was significantly shorter for PSMA PET+ versus PSMA PET- patients by CI (P-value: 0.006, HR: 2.39 CI: 1.3, 4.5) which remained after PSM (P-value: 0.012, HR: 3.0 CI: 1.2, 7.5). Conclusions: In this retrospective, multi-institutional study we investigated the association of oncologic outcomes in a LAHR PCa population receiving RP as definitive treatment and PSMA PET-CT at time of BCR. Our results show that MFS was 3 times shorter in patients with PSMA PET positive lesions at BCR. It is worth noting that a longer follow-up time may be needed to evaluate a robust association with overall survival. A plan is underway to replicate these analyses with a larger patient population at institutions in the US and Europe, aiming to confirm and extend the robustness of these estimates.

Effect of gold nanoparticles treatment on rats-induced obesity by evaluating body-composition directly and indirectly via bioelectric impedance analysis

Scientific Reports Rana M. Selima, Israa A. Saleem, Mamdouh M. Shawki et al. Feb 10, 2025 DOI: 10.1038/s41598-025-87971-z

Abstract Obesity is a metabolic disease characterized by an imbalance between caloric intake and expenditure, leading to excess fat and increasing the risk of various health conditions. This study compares the anti-obesity effects of gold nanoparticles (AuNPs) to orlistat in an experimental model of induced obesity in Wistar Albino rats. In addition to negative and positive control rats, obese rats were treated with variable daily and weekly doses of AuNPs and daily orlistat for nine weeks. Bioelectric impedance analysis (BIA) and dissection techniques were used to indirectly and directly measure body-composition in all rat groups. Hepatic and renal function and ultrastructure were assessed by blood biochemical and histological examinations to detect treatment-related alterations. High doses of AuNPs reduced body fat, increased muscle mass, improved dyslipidemia, glycemia, and antioxidant effects in obese rats, and restored normal TG, FBG, and MDA levels by reducing obesity-related oxidative damage. Histological and ultrastructural examinations showed that these high doses repaired liver and kidney cells, and reduced fat accumulation and body weight compared to the standard treatment for obesity by orlistat.

Implementation of a digital multimedia tool for prostate cancer patient consultation.

Journal of Clinical Oncology Kristin Walker, Samira Samadi, Joe Chen et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.345

345 Background: MyCareGorithm, is a digital health tool designed to improve the cancer consultation experience for patients, companions, and physicians. This tool provides audiovisual guides for cancer related evaluation and management. This study aims to evaluate the effectiveness of this tool for both the patient and physician. Methods: In a prospective, IRB-approved, pilot study, 31 patients with prostate cancer and 12 companions from a single institution underwent an initial consult using this digital multimedia tool. They completed a survey of 6 “yes” or “no” questions to evaluate their understanding of their disease and treatment options. Two physicians completed a 7-question survey to evaluate their experience with this tool. Descriptive statistics were used to analyze the data. Results: Over 90% of patients reported this tool helped them better understand their cancer diagnosis, treatment options, and felt their understating of their medical situation and the quality of the consult was enhanced. 100% would recommend this to other patients. Their companions agreed and answered “yes” over 90% of the time in all categories. Comments from patients include phrase “very helpful” multiple times. Physicians agreed 97% of the time that this helped communicating difficult information and enhanced the quality of the consult. Physicians agreed that the patient had a greater understanding of their cancer, treatment, and that they would use this tool again 100% of the time. 94% of physicians agreed this tool improved efficiency and provided a more effective consult. Physician comments described the infographics as “helpful” in several instances. Survey questions and results are shown (Table). Conclusions: Implementing the MyCareGorithm digital health tool resulted in high levels patient satisfaction, comprehension, and enhanced the overall consult experience. Physicians also report high patient satisfaction and comprehension, enhancements to the overall consult, and improved clinical efficiency. The recurring comment from both physicians and patients was “helpful.” The positive results show the value of this digital communication tool. Further studies with a larger cohort and other disease sites should be assessed. Patient, companion, and physician survey questions and results. Survey Questions % Patients Agreed % Companions Agreed % Physicians Agreed Helped patient greater understand their prostate cancer 97% 100% 100% Helped patient greater understand treatment 90% 100% 100% Enhanced the quality of the consultation 97% 100% 97% Helped patient greater understand their medical situation 100% 100% - Would recommend this tool to other patients 100% 100% 100% Would review the information after consult 84% 92%* - Improved efficiency of the consultation - - 94% Helped physician provide more effective consult - - 94% Helped ease communication of complex information - - 97%

Impact of bleomycin shortage in patients with advanced testicular non-seminoma germ-cell tumors: A middle-income country cancer center experience.

Journal of Clinical Oncology Nora Sobrevilla-Moreno, Josette Staufert-Gutiérrez, Ruben Rodriguez-Bautista et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.623

623 Background: Standard of care for advanced NSGCTs is BEP (bleomycin, etoposide, cisplatin). Social, epidemiologic and economic factors can impact drug availability. In our institution, the COVID-19 pandemic limited accessibility to several antineoplastic drugs, including bleomycin. This analysis describes the frequency of BEP modifications and its impact in prognosis of intermediate (IP) and poor (PP) NSGCT treated at the National Cancer Institute in Mexico. Methods: Retrospective observational study performed from 2018 to 2022. Clinical characteristics and chemotherapy modifications were retrieved from electronic charts. Survival curves were built with Kaplan-Meier method and compared log-rank test to demonstrate effects of different clinicopathological variables on survival. Statistically significant variables in univariate analysis were included in multivariate Cox regression. Results: 179 patients included. Median age 23 (16-56). 33% had IP and 66% PP; 32% had non-pulmonary visceral metastases (NPVM). 60% had at least one dose modification. Median dose of bleomycin was 67.5 IU (IQR, IU 0-90) per cycle. 42% of patients received the full-dose of bleomycin (Bleo360) dose. 55.8% of bleomycin modifications were due to drug shortage. 88% who received Bleo360 didn´t have other chemotherapy drug modifications (p<.001). Median Progression Free Survival (mPFS) was 17.4 months (95% Confidence Interval (CI), 11.8-23.1). Median Overall Survival (mOS) was 73.6 months (95% CI, 20.6-126.7). Univariate and multivariate analysis are described in the table. Conclusions: Oncology drug shortages may have serious consequences for patient’s survival. In our cohort the dose-modifications of bleomycin had a deleterious impact in the survival of IP/PP NSGCTs patients. Policy modifications and stakeholders awareness is paramount to decrease shortage of “vintage” oncological therapies. Univariate and multivariate analysis. Univariate Multivariate Variable PFS HR(IC 95%) p OS HR(IC 95%) p PFS HR(IC 95%) p OS HR(IC 95%) p IPPP 0.34(0.21-0.56) <0.0001 0.3(0.2-0.5) 0.0001 Ref.2.4(1.4-4.2) 0.002 Ref.2.8(1.5-5.5) 0.002 NPVMNoYes 0.53(0.36-0.78) 0.001 0.5(0.4- 0.9) 0.011 Ref.1.3(0.9-2) 0.2 Ref.1.1(0.7-1.9) 0.6 Bleo360YesNo 0.6(0.66-0.98) 0.04 0.63(0.39-1.0) 0.06 Ref.1.3(0.9-2.0) 0.1 Ref.1.3(0.8-2.1) 0.3 Log Tumor MarkerFavorableUnfavorable 0.51(0.30-0.84) 0.009 Ref.2.1(1.2-3.7) 0.008 Ref.1.6(0.9-2.9) 0.1

Outcomes of enfortumab vedotin and pembrolizumab for patients previously treated with immune checkpoint inhibitors in the UNITE study.

Journal of Clinical Oncology Tanya Jindal, Cindy Y. Jiang, Omar Alhalabi et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.867

867 Background: In trials testing enfortumab vedotin and pembrolizumab (EVP), prior treatment with immune checkpoint inhibitors (ICIs) was not permitted, resulting in a knowledge gap regarding efficacy of EVP in patients (pts) previously treated with ICIs. We hypothesized that EVP would have efficacy in pts with prior ICI exposure. Methods: In the retrospective UNITE study, we identified all pts treated with ICI prior to receiving EVP. The observed response rate (ORR) was assessed in evaluable pts who had imaging after ≥1 cycle of EVP. The following factors were evaluated to assess effect on EVP outcomes: type of ICI received (PD-1 vs PD-L1), prior pembrolizumab vs other ICI, time from last ICI to start of EVP, duration on prior ICI treatment, whether patient had clinical benefit (SD/PR/CR) to prior ICI, whether ICI was the immediate prior therapy line and whether it was the only prior line. ORR for these categories was compared using logistic regression, while progression-free survival (PFS) and overall survival (OS) from EVP start were analyzed using the log-rank test and Cox proportional hazards model. Results: Among 220 pts treated with EVP across 10 US sites, 43 (20%) had previously received ICI. Median age was 69 years; 34 (79%) were men, 40 (93%) were Caucasian, and 27 (63%) had pure urothelial carcinoma, 9 (21%) liver mets and 31 (72%) ECOG PS 0/1. Of 43 pts, 4 received ICI in the peri-operative setting (3 nivolumab, 1 pembrolizumab) and 39 in the metastatic setting (19 pembrolizumab, 8 avelumab maintenance, 6 nivolumab, 2 pembrolizumab maintenance and 1 each of atezolizumab, ipilimumab/nivolumab, durvalumab/tremelimumab, nivolumab/NKTR214). ORR was 48% (95% CI: 31 - 66) in 33 evaluable pts, with 13 (39%) PR and 3 (9%) CR; 30% had SD as best response (DCR 79%), and 21% PD. After median follow-up of 14 mos, median PFS was 6.9 mos (95% CI: 3.91 – 12.2) and median OS 15.4 mos (95% CI: 8.7 – NR). Outcomes by group are shown in the Table. Conclusions: Pts treated with EVP after prior ICI experienced high ORR and disease control rate. Results from this multi-site retrospective study are hypothesis-generating and require prospective validation in larger cohorts. Groups ORR PFS OS OR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value Type of ICI (PD-1 vs PD-L1) 2.15 (0.36 – 17.49) 0.4 0.72 (0.32 – 1.61) 0.4 0.59 (0.23 -1.52) 0.3 Prior pembrolizumab vs not 0.54 (0.12 – 2.23) 0.4 0.55 (0.26 – 1.16) 0.1 0.40 (0.15 – 1.02) 0.05 Time from prior ICI* 1.01 (0.98 – 1.05) 0. 5 0.99 (0.98 – 1.01) 0.9 0.98 (0.96 – 1.02) 0.3 Time on prior ICI* 0.87 (0.74 - 0.98) 0.05 0.99 (0.94 – 1.05) 0.9 0.97 (0.89 – 1.05) 0.4 Clinical benefit to prior ICI (DCR vs PD) 0.50 (0.08 – 2.75) 0.4 0.70 (0.27 – 1.81) 0.5 0.89 (0.29 – 2.73) 0.8 Multiple prior lines vs ICI as only prior line 0.51 (0.11 – 2.29) 0.4 1.40 (0.57 – 3.44) 0.5 1.87 (0.54 – 6.43) 0.3 ICI as immediate prior line vs not 0.93 (0.15 -5.82) 0.9 0.56 (0.20 – 1.57) 0.3 0.53 (0.17 – 1.64) 0.3 *Continuous.

An integrated petrophysical and rock physics characterization of the Mangahewa Formation in the Pohokura field, Taranaki Basin

Scientific Reports Shakhawat Hossain, Naymur Rahman Feb 10, 2025 DOI: 10.1038/s41598-025-88639-4

Abstract The Mangahewa Formation in the Pohokura gas field, Taranaki Basin, is a key reservoir for gas production in New Zealand, yet its deep and heterogeneous nature presents challenges for accurate reservoir characterization. While prior studies have explored aspects of the Mangahewa Formation such as lithology, fluid composition, and petrophysical properties, the interrelationships between these factors and their impact on hydrocarbon production remain underexamined. This study integrates detailed petrophysical and rock physics analyses to overcome these challenges. Petrophysical evaluation, based on well log data from depths of 3200–4000 m, reveals net reservoir thicknesses ranging from 164 to 479 m, with total porosity between 17 and 21% and effective porosity between 8 and 19%. Shale volume and water saturation vary from 21–28 and 22–34%, respectively. Rock physics analysis was performed using Rock Physics Templates (RPTs) to model the elastic properties of the reservoir. The Mangahewa Sandstone exhibits elastic properties consistent with the stiff sand model, with compressional sonic velocities ranging from 4100 to 5000 m/s. High correlations were achieved between measured and modeled velocities, with 97% for VP and 94% for VS. These models enabled the estimation of porosity from seismic-derived acoustic impedance, providing valuable insights in areas with limited well control. Furthermore, the RPTs effectively differentiated between gas sand, water sand, and shale facies, minimizing uncertainties in fluid and lithology prediction. These results provide a comprehensive understanding of the Mangahewa Formation, enhancing hydrocarbon prospect evaluation and supporting further exploration and development in the Pohokura field.

Evaluating the efficacy and safety of pelvic lymph node dissection in high-risk prostate cancer patients undergoing radical prostatectomy: A systematic review and meta-analysis.

Journal of Clinical Oncology Qihao Wang, Jianjun Ye, Lei Zheng et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.390

390 Background: Pelvic lymph node dissection (PLND) is currently considered the gold standard for lymph node staging in prostate cancer patients. However, there is a paucity high-quality evidence demonstrating an oncological prognostic benefit of PLND in high-risk prostate cancer (PCa) populations, as defined by D'Amico risk classification. Methods: We conducted a comprehensive systematic literature review utilizing MEDLINE (PubMed), Cochrane Central Register of Controlled Trials (CENTRAL) and EMBASE databases. The search encompassed studies up to June 2024, adhering to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. We identified original articles published in journals that reported survival analyses using Cox regression analysis and differences in hazard ratios (HRs) for the biochemical recurrence (BCR)-free survival (BRFS) (primary outcome) and metastasis-free survival (MFS), overall survival (OS) or cancer specific survival (CSS) (secondary outcomes). A meta-analysis of the effect of PLND on primary and secondary endpoints was performed using a random effects model. Results: Our analysis included seven studies, comprising one prospective and the rest retrospective. Pooled outcome data showed that PLND after radical prostatectomy did not independently predict BRFS (HR: 1.22; 95%CI: 0.99-1.50; p=0.006), MFS (HR: 1.21; 95%CI: 0.86-1.70; p=0.27), OS (HR: 0.91; 95%CI: 0.74-1.12; p=0.37), or CSS(HR: 1.02; 95%CI: 0.74-1.42; p=0.89) in high-risk prostate cancer patients. Heterogeneity was low to moderate. Conclusions: The available pooled analyses suggest that the therapeutic value of PLND is unclear. The high-risk PCa population should be carefully selected for lymph node dissection.

Multimodal management of oligometastatic and oligoprogressive renal cancer patients with extra-lung metastases: The KAIROS study.

Journal of Clinical Oncology Alessandra Dimino, Mimma Rizzo, Ivan Fazio et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.507

507 Background: Patients with oligometastatic (OM-) or oligoprogressive renal cell carcinoma (OP-RCC) may benefit from metastasis-directed therapy (MDT) alone or in combination with systemic therapies. Literature data are available for IMDC favorable-risk patients with low-volume and asynchronous metastases, particularly to the lung. However, OM- and OP-RCC represent a heterogeneous population, and the current knowledge on the use of MDTs on extra-lung metastases remains limited. Methods: This was a real-world, multicenter, observational, retrospective study to assess the Time-to-Subsequent-Systemic-Treatment (TSST) in OM- and OP-RCC patient populations with at least 1 extra-lung metastasis undergoing MDTs [stereotactic body radiation therapy (SBRT), or surgical metastasectomy (SM)], during active surveillance (Cohort 1-OM), or upfront systemic treatments (ST) (Cohort 2-OP), as part of routine clinical care. Results: A total of 138 patients were included: 81 (58.7%) in the OM, and 57 (41.3%) in the OP cohort. Bone (44 lesions, 22.4 %), lymph nodes (33 lesions, 16.8 %), brain (28 lesions, 14.3 %), adrenal gland (26 lesions, 12.3%), soft tissues (14 lesions, 7.1%), liver (11 lesions, 5.6%), contralateral kidney (12 lesions, 6.1%), pancreas (10 lesions, 5.1%), peritoneum (7 lesions, 3.7%) or others (11 lesions, 5.6%) were the sites treated with MDT, for a total of 196 lesions: 139 metastases treated with SBRT (70.9%), and 57 (29.1%) treated with SM. In the Cohort 1-OM, a total of 112 lesions were treated with MDTs: 66 with SBRT (58.9%) and 46 with SM (41.1%). The median TSST was 43.0 months (95%CI 24.09-61.90); 73.2% and 60.5% of patients were free from systemic therapy at 1 and 2 years, respectively. In the Cohort 2-OP, 84 oligoprogressive lesions were treated: 73 with SBRT (86.9%) and 11 with SM (13.1%). Concomitant ST were: Tyrosine Kinase Inhibitors (TKIs) alone (25 pts, 43.9%), immune-oncology (IO) combination [IO-TKI (16 pts, 28.1%) or IO-IO (2 pts, 3.5%)], nivolumab (12 pts, 21.0%) or everolimus ± TKI (2 pts, 3.5%). The median TSST was 31.0 months (95%CI 24.32-37.68); freedom from subsequent systemic therapy at 1 and 2 years was 66.7% and 45.6%, respectively. Safety profile was favorable, with 1 Grade 3 and any Grade 4 SBRT-related toxicities or surgical complications reported. Conclusions: OM and OP-RCC do not have a clear standard of care, and data supporting the multimodal management of extra-lung metastases are lacking. Our real-world data suggest that the use of the SBRT and SM for the treatment of extra-lung metastases in patients undergoing AS or ST can be a useful strategy within a multidisciplinary approach, allowing the delay of systemic treatment initiation or escalation, with favorable toxicity rates.

Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL

Journal of Clinical Oncology Gregory W. Roloff, Ibrahim Aldoss, Noam E. Kopmar et al. Feb 10, 2025 DOI: 10.1200/jco.24.00321

PURPOSE On the basis of the results of the ZUMA-3 trial, brexucabtagene autoleucel (brexu-cel), a CD19-directed chimeric antigen receptor T-cell therapy, gained US Food and Drug Administration approval in October 2021 for adults with relapsed/refractory (R/R) B-cell ALL (B-ALL). We report outcomes of patients treated with brexu-cel as a standard therapy. METHODS We developed a collaboration across 31 US centers to study adults with B-ALL who received brexu-cel outside the context of a clinical trial. Data were collected retrospectively from October 2021 to October 2023. Toxicities were graded per American Society for Transplantation and Cellular Therapy guidelines for cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS). RESULTS At the time of data lock, 204 patients had undergone apheresis and 189 were infused. Median follow-up time was 11.4 months. Forty-two percent of patients received brexu-cel in morphologic remission and would have been ineligible for participation in ZUMA-3. After brexu-cel, 151 achieved complete remission (CR), of which 79% were measurable residual disease (MRD) negative remissions. Median progression-free survival (PFS) was 9.5 months and median overall survival was not reached. Grade 3-4 CRS or ICANS occurred in 11% and 31%, respectively. In multivariable analysis, patients receiving consolidative hematopoietic cell transplantation (HCT; hazard ratio, 0.34 [95% CI, 0.14 to 0.85]) after brexu-cel had superior PFS compared with those who did not receive any consolidation or maintenance therapy. CONCLUSION Similar to ZUMA-3, high rates of MRD-negative CR were observed after brexu-cel treatment for R/R B-ALL. The use of HCT as consolidation after brexu-cel resulted in improved PFS.

Scheduling optimization based on particle swarm optimization algorithm in emergency management of long-distance natural gas pipelines

PLoS ONE Huichao Guo, Runhua Huang, Shuqin Cheng Feb 10, 2025 DOI: 10.1371/journal.pone.0317737

This paper aims to solve the scheduling optimization problem in the emergency management of long-distance natural gas pipelines, with the goal of minimizing the total scheduling time. To this end, the objective function of the minimum total scheduling time is established, and the relevant constraints are set. A scheduling optimization model based on the particle swarm optimization (PSO) algorithm is proposed. In view of the high-dimensional complexity and local optimal problems, the neighborhood adaptive constrained fractional particle swarm optimization (NACFPSO) algorithm is used to solve it. The experimental results show that compared with the traditional particle swarm optimization algorithm, NACFPSO performs well in both convergence speed and scheduling time, with an average convergence speed of 81.17 iterations and an average scheduling time of 200.00 minutes; while the average convergence speed of the particle swarm optimization algorithm is 82.17 iterations and an average scheduling time of 207.49 minutes. In addition, with the increase of pipeline complexity, NACFPSO can still maintain its advantages in convergence speed and scheduling time, especially in scheduling time, which further verifies the optimization effect of the algorithm in emergency management.

A frequency attention-embedded network for polyp segmentation

Scientific Reports Rui Tang, Hejing Zhao, Yao Tong et al. Feb 10, 2025 DOI: 10.1038/s41598-025-88475-6

Population-based assessment of treatment patterns for high-risk localized prostate cancer.

Journal of Clinical Oncology Christopher J.D. Wallis, Shawn Malone, Ilias Cagiannos et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.349

349 Background: Patients diagnosed with high- or very high risk (H/vHR) prostate cancer (PCa) are at substantial risk of disease recurrence, metastasis, and death after treatment. Historically, treatment paradigms for these patients have been similar to those with intermediate-risk (IR) disease [radiotherapy (RT) with androgen deprivation therapy (ADT) and radical prostatectomy (RP)] though there is a growing body of evidence supporting intensified systemic therapy in this group. To contextualize this emerging trial data, we characterized real world treatment patterns for these patients. Methods: We performed a retrospective population-based cohort study using province-wide linked administrative data in Ontario, Canada. We descriptively characterized initial treatment patterns (within 1 year of diagnosis) for men with H/vHR PCa and compared them to a concurrent cohort of patients with IR disease to assess differences in management. Results: We identified 13,206 patients diagnosed with H/vHR PCa from 2010-2021 who were compared to 18,365 with IR disease. Most patients received active treatment, though rates were statistically significantly higher in the H/vHR (n=12,606, 95.5%) than IR cohort (n=14,995, 81.6%; p<0.001; standardized diff 0.44). 6207 (47%) of patients in the H/vHR cohort and 7286 (40%) of patients in the IR cohort underwent RP (p<0.001; standardized difference 0.148). Median time to RP was 98 days in the HR cohort and 105 days in the IR cohort (Median time (Q1-Q3); p<0.003; standardized difference 0.11). 6321 (47.9%) of those with H/vHR disease and 7427 (40.4%) of those with IR disease underwent radiotherapy (p<0.001; standardized difference 0.150). Very few patients received intensified systemic therapy: 77 patients (0.2%) received chemotherapy and 49 (0.2%) received androgen receptor pathway inhibitors. While treatment patterns were similar, patients with H/vHR disease were more likely to progress to metastasis (46% vs 30%, p<0.001) and more rapidly (2.6 vs 4.3 years, p<0.001), with similar patterns observed for CRPC, mCRPC treatment, prostate cancer events, and death. Conclusions: Despite higher rates of treatment, patients with H/vHR localized disease experience significantly worse clinical outcomes than those with IR. These data highlight the need for therapies which can improve clinical outcomes in this patient population, such as the potential use of intensified systemic therapies including Androgen Receptor Pathway Inhibitors (ARPIs).

Effectiveness and safety of RC48-ADC in combination with toripalimab as neoadjuvant treatment in HER2-positive muscular invasive urothelial bladder cancer patients.

Journal of Clinical Oncology Chenglong Li, Jiefu Zhu, Fan Cheng et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.710

710 Background: Bladder cancer with high expression of human epidermal growth factor receptor 2 (HER2) is associated with pathological malignancy and poor prognosis. For patients with muscle-invasive bladder cancer that can be curative resected, the standard treatment is radical cystectomy and pelvic lymph node dissection following neoadjuvant chemotherapy (NAC). However, NAC is inefficient, and many patients cannot tolerate its adverse reactions. Therefore, a novel and safe strategy for these patients is needed after NAC. Methods: In this study, patients with muscle-invasive bladder cancer (MIBC) diagnosed with cT2a-4aN0M0 who were HER2 positive (HER2 IHC1+, 2+, or 3+) and intolerant to platinum underwent transurethral resection of bladder tumor (TURBT). This was followed by 4 cycles of toripalimab (200 mg, intravenous, D1, Q2W) combined with disitamab vedotin (2 mg/kg, intravenous, D1, Q2W) as neoadjuvant therapy. For patients who requested bladder preservation, we performed Re-cTURBT or multipoint biopsy to verify the status of residual tumors in the bladder. The primary endpoint was pathological complete response (pCR). Secondary endpoints included objective response rate (ORR), overall survival (OS), and safety. Results: A total of 28 patients were enrolled from April 2023 to Jun 2024 in our hospital. The median age was 68 years (range: 55-82). By the data cut-off in June 2024, 16 patients (57.1%) achieved clinical complete response (cCR). Among those who achieved cCR, the primary endpoint of pCR was 93.7% (15/16). The median follow-up time was 11.8 months. The median OS was not reached, ORR was 96.4% (27/28). Regarding safety, treatment-related adverse events (TRAEs) of any grade occurred in 21 patients (75%). The most common TRAEs were fatigue (68.3%), itching (57.5%), poor appetite (51.2%), alopecia (33.3%), and diarrhea (16.7%), all of which are grade 1-2. Grade 3 TRAE occurred in 4 patients (14.3%), with one patient experiencing cardiac tachycardia (3.5%) and 3 patients having hepatic dysfunction (10.7%). No grade 4 and 5 TRAEs were observed. Conclusions: Disitamab vedotin (RC48-ADC) combined with toripalimab as neoadjuvant treatment has shown excellent effectiveness and safety in curative resectable MIBC patients with HER2 positive. Those who achieved cCR and underwent Re-cTURBT and multipoint biopsy in bladder had an excellent pCR.

Patient characteristics and overall survival with lutetium (Lu <sup>177</sup> ) vipivotide tetraxetan ( <sup>177</sup> Lu-PSMA-617): A real-world analysis of early adopters.

Journal of Clinical Oncology Daniel J. George, Neal D. Shore, Jennifer Nguyen et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.63

63 Background: 177 Lu-PSMA-617, a prostate-specific membrane antigen (PSMA)-targeting radioligand therapy for metastatic castration-resistant prostate cancer (mCRPC), received FDA approval in March 2022 for the treatment of adult patients with PSMA-positive mCRPC who have received both an androgen receptor pathway inhibitor (ARPI) and a taxane-based chemotherapy. Outside of clinical trials, limited real-world evidence evaluating the effectiveness of 177 Lu-PSMA-617 has been reported. The aim of the current study was to evaluate patient characteristics and overall survival (OS) among patients diagnosed with mCRPC who were treated with 177 Lu-PSMA-617 within a large-scale real-world cohort. Methods: This retrospective, observational study used the IQVIA PharMetrics Plus claims data from July 1, 2013 to December 31, 2023, and linked social determinants of health data as well as mortality data to obtain month and year of death. Adult men with mCRPC who had received 177 Lu-PSMA-617 were included (first receipt of 177 Lu-PSMA-617 = index date). Patient demographics and characteristics were evaluated descriptively; patient demographics were reported on the index date and clinical characteristics were evaluated over the 12 months prior to index date. OS was measured from the start of the first 177 Lu-PSMA-617 treatment until death or end of available follow-up, and assessed using Kaplan–Meier analysis. Results: A total of 643 patients were included in the analysis; median age was 69 years. Treatment for the majority of patients (490/643 [76.2%]) was managed by oncologists (169 [26.3%] of which had specialty in radiation oncology). White patients (292 [72.8%]) made up the largest part of the patient population followed by Black (37 [9.2%]), Hispanic (23 [5.7%]), and Asian (8 [2.0%]). Most patients had multiple comorbidities with either one (226/643 [35.1%]) or two (224/643 [34.8%]) sites of metastasis. Most patients experienced bone metastases (581/643 [90.4%]); 284/643 (44.2%) also experienced visceral metastases of which the liver was the most common site (78/643 [12.1%]). The median OS from start of 177 Lu-PSMA-617 therapy was 15.3 months (95% confidence interval [CI]: 14.6–16.3); a total of 137/643 (21.3%) patients died. OS was analyzed in different patient subgroups and no major differences were observed by metastatic site, number of metastatic sites, race, or age. Conclusions: To our knowledge, this is the first large-scale study reporting OS with 177 Lu-PSMA-617 in clinical practice. OS observed with 177 Lu-PSMA-617 in this study (median: 15.3 months) was consistent with results from the VISION Phase III clinical trial (median: 15.3 months; NCT03511664). Furthermore, 177 Lu-PSMA-617 demonstrated similar survival across different patient subgroups.

In Silico identification and characterization of SOS gene family in soybean: Potential of calcium in salinity stress mitigation

PLoS ONE Anam Hameed, M. Asaf Khan, M. Hammad Nadeem Tahir et al. Feb 10, 2025 DOI: 10.1371/journal.pone.0317612

Leguminous crops are usually sensitive to saline stress during germination and plant growth stages. The Salt Overly Sensitive (SOS) pathway is one of the key signaling pathways involved in salt translocation and tolerance in plants however, it is obscure in soybean. The current study describes the potential of calcium application on the mitigation of salinity stress and its impact on seed germination, morphological, physiological and biochemical attributes of soybean. The seeds from previously reported salt-tolerant and salt-susceptible soybean varieties were primed with water, calcium (10 and 20 mM), and stressed under 60, 80 and 100 mM NaCl and evaluated in various combinations. Results show that germination increased by 7% in calcium primed non-stressed seeds under non-stressing, whereas an improvement of 15%-25% was observed in germination under NaCl stress. Likewise, improvement in seedling length (3%-8%), plant height (9%-18%), number of nodes (3%-14%), SOD activity (20%) and Na+/K+ concentration (3%-5% reduction) in calcium primed plants, indicates alleviation of salinity-induced negative effects. In addition, this study also included in silico identification and confirmation of presence of Arabidopsis thaliana SOS genes orthologs in soybean. The research of amino acid sequences of SOS proteins from Arabidopsis thaliana (AtSOSs) within Glycine max genome displayed protein identity (60–80%) thus these identified homologs were called as GmSOS. Further phylogeny and in silico analyses showed that GmSOS orthologs contain similar gene structures, close evolutionary relationship, and same conserved motifs, reinforcing that GmSOSs belong to SOS family and they share many common features with orthologs from other species thus may perform similar functions. This is the first study that reports role of SOSs in salt-stress mitigation in soybean.

The internet usage increases fear of infection with Covid-19

Scientific Reports Youzhi Xiao Feb 10, 2025 DOI: 10.1038/s41598-025-88283-y

Outcomes of patients with stage I testicular cancer following orchidectomy with borderline retroperitoneal lymph node enlargement at diagnosis.

Journal of Clinical Oncology Deepro Chowdhury, Eshetu G. Atenafu, Di Maria Jiang et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.633

633 Background: Approximately 60% of men diagnosed with testicular cancer present with Stage I disease. Most metastases occur in the retroperitoneal lymph nodes (RPLN); RPLN measuring 8-10 mm in the long axis in the appropriate landing zone are considered highly suspicious, and those measuring &gt; 10 mm usually receive additional surgery, chemotherapy or radiation. Many of these patients’ (pt) RPLN will spontaneously regress without additional treatment. Our goal is to better understand the incidence, natural history, and predictors of such spontaneous RP nodal regressions. Methods: We performed a retrospective chart review of clinical records and staging CT imaging reports from all pts followed at Princess Margaret Cancer Centre (PM) from 2004 – 2024 with Stage I-IIA testicular cancer following orchidectomy. Our primary outcome of interest was the 5-year relapse-free survival (RFS, calculated using the Kaplan–Meier method) of pts with testicular cancer with borderline RPLN (longest dimension 8-14 mm based on first CT scan done within 60 days of orchidectomy) in the appropriate landing zone with no other sites of metastases, and declining or normal tumor markers (AFP, HCG and/or LDH) post-orchiectomy who were initially managed with active surveillance according to a pre-determined schedule with additional interim assessments as deemed appropriate by the treating team. Secondary outcomes included identifying histopathologic predictors of relapse in pts who ultimately went on to require further treatment using a Cox proportional-hazards model. Results: Of the 1535 pts with Stage I-IIA disease, 126 had borderline enlarged RPLN (8.2%). 63.7% were pure seminoma (SEM) and 36.3% were non-seminoma germ cell tumors (NSGCT). Incidence of right, left, and bilateral primaries was 47.6%, 50.8% and 1.6% respectively. Median age at consultation was 33 (SEM; range 19-59) vs 27 (NSGCT; range 19-49) years. Median follow-up was 61.9 (5.8 – 203) months. 5-year RFS was 56% (95% CI 46%-64%) in the entire cohort, 61% (95% CI 49%-71%) in SEM and 48.9% (95% CI 33.7%-62.4%) for NSGCT (p = 0.024 SEM vs NSGCT). Median time to relapse (TTR) was 15.8 (95% CI 6.5-25.0) weeks. 5-year OS was 100% regardless of relapse status. Pure embryonal carcinoma (EC) histology (p = 0.014) and LVI (p = 0.03) were associated with subsequent relapse. Rete testes invasion, primary tumor size, largest LN diameter and number of suspicious nodes were not associated with relapse (p &gt; 0.05 for all). Conclusions: It is reasonable to consider careful close interval follow-up and active surveillance in pts with borderline RPLN and falling or negative tumor markers. Short interval follow-up CT scan (6-8 weeks) after orchidectomy to re-evaluate borderline RPLN may spare overtreatment of men who have been cured with orchiectomy alone. EC histology and LVI were independent predictors of relapse.

Impact of tumor burden or focality in recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer on response to treatment with UGN-102: A substudy of the phase 3 ENVISION trial.

Journal of Clinical Oncology Sandip M Prasad, Dimitar Shishkov, Nikola V Mihaylov et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.776

776 Background: The ENVISION phase 3 study (NCT05243550) treated patients withlow-grade intermediate-risk non-muscle-invasive bladder cancer (LG-IR-NMIBC) with UGN-102, a reverse thermal hydrogel containing mitomycin. Primary efficacy and safety results were previously reported. Complete response (CR) rate at 3 months was 79.6%, with an 82.3% probability of remaining in response 12 months later by Kaplan-Meier estimate. We conducted a post-hoc analysis to evaluate if certain tumor characteristics influenced response rate and durability. Methods: In the single-arm ENVISION study, 240 patients with LG-IR-NMIBC received at lease one dose of UGN-102, 95% (228) received all 6 weekly doses; 3 months after the first dose, patients were examined for the presence of bladder cancer using cystoscopy, urine cytology testing, and for-cause biopsy. Patients achieving CR (no detectable disease) entered the follow-up period and were surveilled regularly for recurrence. Between group comparisons were performed for CR rate (CRR) at 3 months and duration of response (DOR) 12 months after achieving CR in patients with tumor burden ≤ or &gt;3 cm (calculated as total length of all tumors), and for single vs multiple tumors. Hazard ratios (HRs) of DOR were calculated using a Cox Proportional Hazards (PH) model, and p-values calculated using a log-rank test; p-values for the comparison of CRR were calculated using Fisher’s Exact Test. Results: CRR at 3 months was 82.8% vs 73.2% for patients with tumor burden ≤3 cm and &gt;3 cm, respectively. Of the patients with CR at 3 months, 15.4% vs 20% experienced recurrence of LG disease, progression (either in stage or grade), or death by 15 months. In patients with multiple vs single tumors, 3-month CR was 79.3% vs 82.9%, with recurrence rates of 18.5% vs 11.8%. DOR HRs were not statistically significant for any comparison made (table). Conclusions: Although a non-significant higher event rate was observed at 3 months for patients with a higher tumor burden, the CRR was robust, and the majority of patients remained event free at 15 months. These results demonstrate that chemoablation using UGN-102 results in a high, clinically meaningful CRR in patients with recurrent LG-IR-NMIBC, regardless of tumor burden or multifocality. Study limitations were the small sample size of the comparator groups, single arm design, and post-hoc nature of the analysis. UGN-102 may represent a valuable treatment option for many patients with LG-IR-NMIBC. Clinical trial information: NCT05243550 . CR at 3 months CRR(95% CI) / p value* Recurrence within 15 months DOR HR(95% CI) / p value* Tumor size ≤3 cm&gt;3cm 149/180 (82.8%)30/41 (73.2%) 1.13 (0.93–1.38) / p=0.1854 23/149 (15.4%)6/30 (20.0%) 0.777 (0.317–1.909) / p=0.5816 Tumor count MultipleSingle 157 /198 (79.3%)34/41 (82.9%) 0.96 (0.82 –1.12) / p=0.6740 29/157 (18.5%)4/34 (11.8%) 1.644 (0.578–4.677) / p=0.3459 *Nominal.

Liver Transplantation for Hepatocellular Carcinoma: An Expanding Cornerstone of Care in the Era of Immunotherapy

Journal of Clinical Oncology Christian Tibor Josef Magyar, Grainne Mary O'Kane, Laia Aceituno et al. Feb 10, 2025 DOI: 10.1200/jco.24.00857

Liver transplantation (LT) has been accepted as a cornerstone of care in hepatocellular carcinoma (HCC) for almost three decades. In recent years, its role has been evolving to include patients with disease burden beyond the widely used Milan criteria. The integration of dynamic biomarkers such as alpha-fetoprotein together with downstaging approaches and tumor evolution after enlistment has allowed the selection of patients most likely to benefit, resulting in 5-year survival rates greater that 70%. With the increasing use of immune checkpoint inhibitors (ICIs) across all stages of disease, alone or in combination with locoregional therapies, there is now the potential to further expand the patient population with HCC who may benefit from LT. This brings challenges, given the global shortage of organs and the need to better understand the optimal use of ICIs before transplantation. Furthermore, the field of transplant oncology awaits additional biomarkers that can predict those likely to benefit from ICIs. More than ever, a multidisciplinary approach for liver cancer management is critical to ensure all patients are considered for LT where appropriate, and do not miss the opportunity for long-term survival.

Factors influencing sepsis associated thrombocytopenia (SAT): A multicenter retrospective cohort study

PLoS ONE Lu Wang, Jieqing Chen, Xiang Zhou Feb 10, 2025 DOI: 10.1371/journal.pone.0318887

Introduction Sepsis associated thrombocytopenia (SAT) is a common complication of sepsis. We designed this study to investigate factors influencing SAT. Methods Patients with sepsis (2984 in Peking union medical college hospital [PUMCH] database, 13165 in eICU Collaborative Research [eICU] database, 11101 in Medical Information Mart for Intensive Care IV [MIMIC-IV] database) were enrolled. Variables included basic information, comorbidities, and organ functions. Multi-variable logistic regression models and artificial neural network model were applied to determine the factors related to SAT. Main results Age and body mass index (BMI) were inversely correlated with the incidence of SAT (p-value 0.175 and 0.049 [PUMCH], p-value 0.000 and 0.000 [eICU], p-value 0.000 and 0.000 [MIMIC-IV]). Hematologic malignancies and other malignancies were positively correlated with the incidence of SAT (p-value 0.000 and 0.000 [PUMCH], p-value 0.000 and 0.000 [eICU], p-value 0.000 and 0.020 [MIMIC-IV]) except other malignancies was inversely correlated with the incidence of SAT in PUMCH database. Norepinephrine (NE) equivalents, total bilirubin (TBIL) and creatinine were positively correlated with the incidence of SAT (p-value 0.000, 0.000 and 0.011 [PUMCH], p-value 0.028, 0.000 and 0.013 [eICU], p-value 0.028, 0.000 and 0.027 [MIMIC-IV]). PaO2 / FiO2 was inversely correlated with the incidence of SAT in PUMCH database (p-value 0.021 [PUMCH]), while it was positively correlated with the incidence of SAT (p-value 0.000 [MIMIC-IV]). PaO2 / FiO2 and SAT was not related (p-value 0.111 [eICU]). TBIL, hematologic malignancies, PaO2 / FiO2 and NE equivalents ranked in the top five significant variables in all three datasets. Conclusions Hematologic malignancies and other malignancies were positively correlated with the incidence of SAT. NE equivalents, TBIL and creatinine were positively correlated with the incidence of SAT. TBIL, hematologic malignancies, PaO2 / FiO2 and NE equivalents ranked in the top significant variables in factors influencing SAT.